Innogenetics offers new HPV assay

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Innogenetics entered the field of human papillomavirus (HPV) diagnostic testing with the announcement of its new assay, the INNO-LiPA HPV Genotyping CE, at the 23rd International Papillomavirus Congress and Clinical Workshop in Prague.

The biopharmaceutical company said its HPV diagnostic test encompasses the genotypes 6, 11, 16 and 18 that are present in the most advanced prophylactic vaccines.

Infection with HPV genotypes 16 and 18, among others, is associated with the development of cervical cancer, the second most common cause of cancer-related deaths in women worldwide, according to a news release.

Innogenetics, based in Belgium, expects formal CE-marking of the INNO-LiPA HPV Genotyping CE in October.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.